Matthew Klein, PTC Therapeutics CEO
PTC claims PhIII win in rare genetic disease
A PTC Therapeutics treatment for phenylketonuria, a rare disease that can cause a toxic build-up of an amino acid, met the primary endpoint in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
